ABBV — AbbVie Inc.

AbbVie Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Adjusted Earnings Per Share (EPS): $2.65, exceeding guidance by $0.07.
• Total Net Revenues: $15 billion, up 12.4% year-over-year, surpassing expectations by $300 million.
• Adjusted Gross Margin: 83.6% of sales.
• Adjusted R&D Expense: 15.1% of sales.
• Adjusted SG&A Expense: 22.7% of sales.
• Adjusted Operating Margin: 40.8%, impacted by a 5% unfavorable effect from acquired IPR&D expense.
• Net Interest Expense: $645 million.
• Adjusted Tax Rate: 15.4%.

2. Strategic Updates and Business Highlights

• AbbVie is raising its full-year adjusted EPS guidance to between $14.08 and $14.28, reflecting strong performance across its portfolio.
• Immunology Segment:
  • Skyrizi: Total sales of $4.5 billion, up 29.2%, with strong performance in psoriatic disease and IBD.
  • Rinvoq: Global sales of $2.1 billion, up 20.2%, with growth in gastroenterology and rheumatology.
  • HUMIRA: Sales declined 40.3% to $688 million due to biosimilar competition.
• Neuroscience Segment: Revenues of nearly $2.9 billion, up 24.3%, driven by strong sales of migraine treatments and Vraylar.
• Oncology Segment: Revenues over $1.6 billion, down 3%, with Venclexta showing growth but IMBRUVICA declining due to pricing pressures.
• Aesthetics Segment: Sales of nearly $1.2 billion, up 5.1%, with Botox showing strong growth.
• Significant R&D advancements include submissions for Rinvoq in alopecia areata and Skyrizi for Crohn's disease, alongside promising data from ongoing studies.

3. Forward Guidance and Outlook

• Full-year net revenue forecast raised to approximately $67.3 billion, with specific product revenue expectations:
  • Skyrizi: $21.6 billion.
  • Rinvoq: $10.2 billion.
  • Neuroscience: $12.6 billion.
• Anticipated adjusted operating margin ratio of approximately 47.5% for the year.
• Guidance for Q2 includes net revenues of approximately $16.7 billion and adjusted EPS between $3.74 and $3.78.

4. Bad News, Challenges, or Points of Concern

• HUMIRA Sales Decline: The significant drop in HUMIRA sales due to biosimilar competition is expected to continue impacting overall revenues.
• Competitive Pressures: Increased competition in immunology, particularly with the introduction of new oral therapies, poses a risk to Skyrizi and Rinvoq market shares.
• Aesthetics Market Headwinds: The aesthetics business is experiencing slower growth compared to previous economic downturns, attributed to lingering inflationary pressures.
• IRA Pricing Impact: The oncology segment faces challenges from pricing pressures, particularly affecting IMBRUVICA.

5. Notable Q&A Insights

• Competitive Landscape for Skyrizi: AbbVie remains confident in Skyrizi's market position despite emerging competition, citing superior efficacy and strong physician preference.
• Pipeline Development: Discussions on the combination therapies in immunology and the potential for next-generation therapies are ongoing, with AbbVie emphasizing its commitment to innovation.
• M&A Strategy: AbbVie is open to pursuing acquisitions to enhance its pipeline, particularly in neuroscience, oncology, and obesity, while operating from a position of financial strength.
• Tavapadon in Parkinson's Disease: Expected to complement existing therapies, with a focus on younger patients and a favorable safety profile compared to older treatments.
• Obesity Pipeline: AbbVie is optimistic about its long-acting amylin analog, ABBV-295, with potential for significant weight loss and a favorable safety profile.

Overall, AbbVie reported strong Q1 results and raised its guidance, but faces challenges from competitive pressures and market dynamics in certain segments. The company is focused on advancing its pipeline and exploring strategic acquisitions to sustain growth.